Quest Diagnostics (NYSE:DGX) Price Target Increased to $174.00 by Analysts at Mizuho

Quest Diagnostics (NYSE:DGX) had its price target lifted by research analysts at Mizuho from $160.00 to $174.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Mizuho’s target price indicates a potential upside of 12.23% from the company’s previous close.

DGX has been the topic of several other reports. Citigroup increased their target price on shares of Quest Diagnostics from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday. StockNews.com downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday. Truist Financial upped their target price on Quest Diagnostics from $158.00 to $165.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Evercore ISI began coverage on Quest Diagnostics in a report on Wednesday, August 28th. They set an “in-line” rating and a $165.00 price objective for the company. Finally, Piper Sandler raised their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company a “neutral” rating in a research note on Monday, July 29th. Nine research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $163.33.

Quest Diagnostics Trading Down 1.9 %

NYSE:DGX opened at $155.04 on Thursday. Quest Diagnostics has a 1 year low of $123.04 and a 1 year high of $160.95. The stock’s fifty day moving average price is $153.12 and its two-hundred day moving average price is $144.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91. The company has a market cap of $17.22 billion, a P/E ratio of 20.87, a P/E/G ratio of 2.45 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, October 22nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.26 by $0.04. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. The business had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter last year, the company earned $2.22 EPS. The firm’s revenue was up 8.5% compared to the same quarter last year. As a group, analysts expect that Quest Diagnostics will post 8.89 EPS for the current year.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,990 shares of Quest Diagnostics stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total value of $304,987.40. Following the transaction, the senior vice president now directly owns 11,459 shares of the company’s stock, valued at $1,756,206.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Quest Diagnostics

A number of large investors have recently added to or reduced their stakes in DGX. Vanguard Group Inc. boosted its holdings in shares of Quest Diagnostics by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock worth $1,853,151,000 after purchasing an additional 345,754 shares during the period. Davis Selected Advisers raised its holdings in Quest Diagnostics by 0.4% in the second quarter. Davis Selected Advisers now owns 2,390,828 shares of the medical research company’s stock worth $327,257,000 after purchasing an additional 9,665 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Quest Diagnostics by 6.5% during the second quarter. Dimensional Fund Advisors LP now owns 2,109,515 shares of the medical research company’s stock valued at $288,758,000 after buying an additional 129,395 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in shares of Quest Diagnostics by 2.1% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 748,680 shares of the medical research company’s stock valued at $115,621,000 after buying an additional 15,047 shares in the last quarter. Finally, Nuance Investments LLC grew its position in shares of Quest Diagnostics by 13.1% in the 1st quarter. Nuance Investments LLC now owns 681,636 shares of the medical research company’s stock worth $90,733,000 after buying an additional 79,152 shares during the period. Institutional investors own 88.06% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.